查看文章

The aim of the present study was the formulation of a novel chewable tablet containing the non-steroidal anti-inflammatory bumadizone calcium (BZ) to deliver the drug to the colon for the local treatment of ulcerative colitis. Colon targeted granules were prepared following 3² full factorial design. The effect of two independent variables, namely, polymer type (Eudragit ^® S100, Eudragit ^® L100, and a mixture of both in the ratio of 4:1) and drug to polymer ratio (1:1, 1:3& 1:5) on the % of BZ released for 12 h was studied. In order to produce chewability, candidate formulae were then mixed with different amount of maize starch and mannitol, and compressed into tablets. F11 tablets(composed of drug: Eudragit^® S100 in the ratio of 1:3, 250 mg mannitol and 50 mg maize starch with a desirability of 0.925) achieved the required release profile i.e: lowest release before target area (pH 1.2 & 6.8) reaching only 11.00% at the …